Autoantibodies Recognizing Specificity Protein 4 <scp>Co‐occur</scp> With Anti–Transcription Intermediary Factor 1 and Are Associated With Distinct Clinical Features and Immunogenetic Risk Factors in Juvenile Myositis
Matthew A. Sherman(National Institute of Arthritis and Musculoskeletal and Skin Diseases), Iago Pinal‐Fernandez(National Institutes of Health), Andrew L. Mammen(Malaysian Society of Nephrology), Lisa G. Rider(National Cancer Institute), Frederick W. Miller(National Institute of Environmental Health Sciences), Katherine Pak(National Institutes of Health), Willy A. Flegel(National Institutes of Health Clinical Center), Ira N. Targoff(Foundation for Women’s Wellness)
Cited by 14
Related Papers
A New Approach to the Classification of Idiopathic Inflammatory Myopathy
|Medicine|1991|974
Autoimmune-Associated Congenital Heart Block: Demographics, Mortality, Morbidity and Recurrence Rates Obtained From a National Neonatal Lupus Registry
|Journal of the American College of Cardiology|1998|748
Aristolochic acid and the etiology of endemic (Balkan) nephropathy
|Proceedings of the National Academy of Sciences|2007|598
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease
|Lara D. Veeken|2003|367
Molecular Basis of Weak D Phenotypes
|Blood|1999|336